VIENNA — The highly selective oral Janus kinase (JAK) inhibitor SHR0302 (ivarmacitinib) enables more patients with active rheumatoid arthritis to meet American College of Rheumatology (ACR) response ...
Clinical Trials Arena on MSN
Lynk’s selective JAK inhibitor claims Phase III RA win
Lynk’s zemprocitinib commercial partner, Simcere, will now continue the JAK inhibitor’s development across China in RA.
Aclaris Therapeutics has touted the latest phase 2 results for its “soft” JAK 1/3 inhibitor as a win for the beleaguered biotech, but investors appeared less enthusiastic about the wider set of mixed ...
Please provide your email address to receive an email when new articles are posted on . Upadacitinib is an oral JAK inhibitor FDA approved for atopic dermatitis. Upadacitinib demonstrated efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results